OXB Stock Overview
Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally.
Oxford Biomedica plc Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£3.77|
|52 Week High||UK£16.08|
|52 Week Low||UK£3.45|
|1 Month Change||-13.55%|
|3 Month Change||-17.07%|
|1 Year Change||-74.39%|
|3 Year Change||-30.92%|
|5 Year Change||-17.25%|
|Change since IPO||-85.09%|
Recent News & Updates
|OXB||GB Biotechs||GB Market|
Return vs Industry: OXB underperformed the UK Biotechs industry which returned -40.1% over the past year.
Return vs Market: OXB underperformed the UK Market which returned -14.5% over the past year.
|OXB Average Weekly Movement||6.8%|
|Biotechs Industry Average Movement||7.5%|
|Market Average Movement||5.3%|
|10% most volatile stocks in GB Market||10.8%|
|10% least volatile stocks in GB Market||2.6%|
Stable Share Price: OXB is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: OXB's weekly volatility (7%) has been stable over the past year.
About the Company
Oxford Biomedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of cell and gene therapy products in Europe and internationally. The company operates in two segments, Platform and Product. Its LentiVector platform technology integrates genes into non-dividing cells, including neurons in the brain and retinal cells in the eye, as well as accommodates various therapeutic genes.
Oxford Biomedica plc Fundamentals Summary
|OXB fundamental statistics|
Is OXB overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|OXB income statement (TTM)|
|Cost of Revenue||UK£49.68m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.26|
|Net Profit Margin||-19.54%|
How did OXB perform over the long term?See historical performance and comparison